Skip to main content
Premium Trial:

Request an Annual Quote

Genentech Expands ZFP License with Sangamo

NEW YORK (GenomeWeb News) – Sangamo BioSciences has expanded a research and license agreement with Genentech to focus its zinc finger technology on additional targets for production cell lines.
Sangamo’s technology uses naturally occurring transcription factors, called ZFPs, that bind to DNA to regulate gene expression.
Sangamo said the ZFPs engineer ZFNs, which contain a nuclease component that can induce modification of a target gene of interest. Company CEO Edward Lanphier said the firm’s technology offers a “highly specific method to efficiently alter genes in eukaryotic cells.”
Sangamo had a previous agreement with Genentech to design and engineer additional ZFNs that target genes that Genentech is interested in using to improve pharmaceutical production in mammalian cells.

The Scan

Looking for Omicron

NPR reports that SARS-CoV-2 testing in the US has gotten better but also that some experts say more needs to be done to better track the Omicron variant.

Holmes Alleges Abuse

The Associated Press reports that Theranos' Elizabeth Holmes has testified at her wire fraud trial that her business and romantic partner abused her.

Bit More Diverse, But More to Do

While Black and Hispanic patients are more likely to participate in cancer clinical trials than previously, they are still underrepresented, according to US News & World Report.

PNAS Papers on Yeast Gene Silencing, Zika Virus Inhibition, Immunoglobulin Hypermutation

In PNAS this week: gene silencing in Saccharomyces cerevisiae, possible neuroprotective role for SHFL in a mouse model of Zika virus infection, and more.